Efficacy of domperidone plus renal diet in slowing the progression of chronic kidney disease in dogs with leishmaniosis.
Canine
Chronic kidney disease
Leishmania infantum
Serum creatinine
sSDMA
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
31 Oct 2022
31 Oct 2022
Historique:
received:
13
09
2022
accepted:
06
10
2022
entrez:
1
11
2022
pubmed:
2
11
2022
medline:
3
11
2022
Statut:
epublish
Résumé
Chronic kidney disease (CKD) represents the main cause of mortality in dogs with leishmaniosis. Domperidone has recently been reported to improve kidney function in leishmaniotic dogs affected by CKD. Serum symmetric dimethylarginine (sSDMA) has also been shown to be a useful biomarker for earlier detection of decreased kidney function when compared to serum creatinine (sCr). This study aimed to assess the efficacy of domperidone plus renal diet in slowing the progression of nephropathy in leishmaniotic dogs with CKD, evaluating sSDMA and sCr as markers of kidney function. This study was a therapeutic, prospective, randomized, controlled, 11-month-long field trial. Dogs were recruited if classified as "exposed" to or "infected" with Leishmania infantum and affected by CKD at early stages. After enrolment (T0), dogs were randomized into groups T (treatment) and C (control). All dogs were fed a renal diet and then followed up at 90 (T1), 210 (T2), and 330 (T3) days after inclusion in the study. At T1 and T2, dogs in group T received an oral suspension of domperidone (1 ml/10 kg once a day for up to 28 days). Twenty-two dogs (i.e., n = 12 in group T and n = 10 in group C) completed the study. At T0, the entire population of enrolled dogs presented a mean sSDMA value of 16.5 ± 3.4 μg/dl. At T1 (i.e., after 3 months of renal diet), sSDMA was significantly decreased in both groups, with an sSDMA of 13.1 ± 4.4 μg/dl for the entire population involved. From T1 to T3, sSDMA gradually increased in group C, while remaining stable in group T, which continued to show a significantly lower value of sSDMA at T3 than at T0. Regarding sCr, at T0 and T1, the mean values of the entire population of dogs were 1.1 ± 0.3 and 1.0 ± 0.4 mg/dl, respectively, with no statistical differences between groups T and C. In group T, sCr decreased significantly from T0 to T1, while returning at T3 to values similar to T0. In this study, domperidone plus renal diet reduced the progression of kidney disease in leishmaniotic dogs affected by CKD.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic kidney disease (CKD) represents the main cause of mortality in dogs with leishmaniosis. Domperidone has recently been reported to improve kidney function in leishmaniotic dogs affected by CKD. Serum symmetric dimethylarginine (sSDMA) has also been shown to be a useful biomarker for earlier detection of decreased kidney function when compared to serum creatinine (sCr). This study aimed to assess the efficacy of domperidone plus renal diet in slowing the progression of nephropathy in leishmaniotic dogs with CKD, evaluating sSDMA and sCr as markers of kidney function.
METHODS
METHODS
This study was a therapeutic, prospective, randomized, controlled, 11-month-long field trial. Dogs were recruited if classified as "exposed" to or "infected" with Leishmania infantum and affected by CKD at early stages. After enrolment (T0), dogs were randomized into groups T (treatment) and C (control). All dogs were fed a renal diet and then followed up at 90 (T1), 210 (T2), and 330 (T3) days after inclusion in the study. At T1 and T2, dogs in group T received an oral suspension of domperidone (1 ml/10 kg once a day for up to 28 days).
RESULTS
RESULTS
Twenty-two dogs (i.e., n = 12 in group T and n = 10 in group C) completed the study. At T0, the entire population of enrolled dogs presented a mean sSDMA value of 16.5 ± 3.4 μg/dl. At T1 (i.e., after 3 months of renal diet), sSDMA was significantly decreased in both groups, with an sSDMA of 13.1 ± 4.4 μg/dl for the entire population involved. From T1 to T3, sSDMA gradually increased in group C, while remaining stable in group T, which continued to show a significantly lower value of sSDMA at T3 than at T0. Regarding sCr, at T0 and T1, the mean values of the entire population of dogs were 1.1 ± 0.3 and 1.0 ± 0.4 mg/dl, respectively, with no statistical differences between groups T and C. In group T, sCr decreased significantly from T0 to T1, while returning at T3 to values similar to T0.
CONCLUSIONS
CONCLUSIONS
In this study, domperidone plus renal diet reduced the progression of kidney disease in leishmaniotic dogs affected by CKD.
Identifiants
pubmed: 36316751
doi: 10.1186/s13071-022-05537-8
pii: 10.1186/s13071-022-05537-8
pmc: PMC9620618
doi:
Substances chimiques
Biomarkers
0
Domperidone
5587267Z69
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
397Informations de copyright
© 2022. The Author(s).
Références
J Am Vet Med Assoc. 2010 Jun 1;236(11):1192-8
pubmed: 20513197
Parasit Vectors. 2020 Apr 15;13(1):193
pubmed: 32293524
Vet Parasitol. 2020 Jan;277:109015
pubmed: 31874403
J Am Vet Med Assoc. 2002 Apr 15;220(8):1163-70
pubmed: 11990962
Parasit Vectors. 2011 May 20;4:86
pubmed: 21599936
J Anim Physiol Anim Nutr (Berl). 2018 Feb;102(1):297-307
pubmed: 28276099
Am J Physiol. 1990 Nov;259(5 Pt 2):F793-800
pubmed: 1978572
J Am Vet Med Assoc. 2010 Jun 1;236(11):1184-91
pubmed: 20513195
Biology (Basel). 2022 Jan 24;11(2):
pubmed: 35205050
Vet Med Int. 2018 May 13;2018:7517359
pubmed: 29862007
Biomed Res Int. 2018 Mar 29;2018:3296893
pubmed: 29789784
Parasit Vectors. 2015 May 28;8:289
pubmed: 26017164
J Vet Intern Med. 2015 Jul-Aug;29(4):1036-44
pubmed: 26079532
Parasit Vectors. 2021 Oct 10;14(1):525
pubmed: 34629081
Toxicol Pathol. 2021 Jul;49(5):996-1023
pubmed: 33576319
Vet Clin North Am Small Anim Pract. 2016 Nov;46(6):941-60
pubmed: 27499007
Vet J. 2009 Feb;179(2):259-63
pubmed: 18023375
Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):87-95
pubmed: 19054576
Vet J. 2021 Oct;276:105732
pubmed: 34391920
J Small Anim Pract. 2021 Jan;62(1):E1-E19
pubmed: 33107613
Mem Inst Oswaldo Cruz. 2018 Oct 18;113(11):e180301
pubmed: 30365645
Vet Parasitol. 2017 May 30;239:50-56
pubmed: 28495197
Open Vet J. 2016;6(2):121-7
pubmed: 27540513
Vet Parasitol. 2002 Jul 2;106(4):315-24
pubmed: 12079737
PLoS One. 2020 Jun 30;15(6):e0234712
pubmed: 32603378
Res Vet Sci. 2019 Aug;125:218-226
pubmed: 31280121
Clin Vaccine Immunol. 2009 Mar;16(3):337-43
pubmed: 19129471